ArticleBMC public health2025
Effectiveness of a 2-dose varicella vaccination program in Changzhou, China, during the transitional period (2017-2022): a registry-based case-cohort study.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effectiveness of Universal Varicella Vaccination after ten years of implementation in Tuscany (Central Italy).Human vaccines & immunotherapeutics · 2025Article
- Comparison of trend analysis of varicella zoster disease burden between China and the world 1990-2021 and disease burden forecast 2030.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe benefits of improving coverage and timeliness of varicella vaccination need to be quantified in countries where varicella vaccine (VarV) has not yet been included in national immunization programs. This longitudinal study analyzed the vaccine effectiveness (VE) of the varicella vaccination program implemented in Changzhou City during the transitional period (2017-2022).
methodsUsing the Immunization Information System and National Notifiable Infectious Disease Surveillance System registry data, this retrospective case-cohort study assessed the VEs of varicella vaccination for Changzhou children born from 2016 to 2021. The subcohort was sampled using inverse probability weighting for the survival analysis design to evaluate the VEs under different dosages and cost types, eliminating confounding by age and location area. Sensitivity analysis for the exclusion part assessed the study's robustness.
resultsA total of 5,172 children (1.12%) were sampled to the subcohort for studies, including 2,299 cases. VEs significantly rose with each successive dose, reaching 82.54% and 97.91%. VEs were lower for the single-dose subgroups until 2020, with significant increases in VEs in all subgroups in 2020 and after that. Most children who did not benefit from the "1-4" Vaccination Program had lower VEs due to delayed vaccination.
conclusionImproving 2-dose VarV vaccine coverage and timely vaccination could enhance the immune barrier for susceptible children. During the transitional period, the "1-4" Vaccination Program of VarV positively impacted coverage and timeliness in Changzhou.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.